CXCL1 and melanoma: The combination of pharmacologic sEH inhibition and immune checkpoint blockade resulted in decreased gene expression of the pro-inflammatory cytokines Il-6, Cxcl1, Tnfα, Ccl2, and Ccl4 compared to control after 11 d of treatment in the B16F10 melanoma tumor tissue (Fig. 5B).